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Background
As therapeutic vaccination approaches are explored for
cancer therapy, there is a need to identify milestones
that can predict the successful induction of sustained
immunity. We examined whether the magnitude of
immune responses seen prior to vaccination or at the
completion of a vaccine series to a tumor-associated self
antigen can predict long-term immunity.
Methods
Interferon gamma Elispot data was abstracted from
patients enrolled in 3 clinical trials (n = 86) utilizing ther-
apeutic vaccination targeting HER2/neu with long-term
follow-up. A positive response/immunity was defined as a
precursor frequency of greater than 1:20,000 or 50 inter-
feron gamma corrected spots per well/106 peripheral
blood mononuclear cells. Responses were evaluated at
baseline study entry, at one month after completion of
vaccinations and at long-term follow-up, the last time
point available at week 24-36. Correlative statistical analy-
sis was performed using Pearson product-moment corre-
lation coefficients of least-squares regression.
Results
Although the magnitude of immunity at one month post
vaccination and at baseline both correlated with immu-
nity at long-term follow-up, immunity at one month
post-vaccination has the stronger correlation: (p < 0.0001,
r = 0.651) versus (p < 0.0001, r = 0.571). Immunity at
one month post-vaccination predicts positivity at long-
term follow-up (AUC = 0.7872). Defining a threshold of
greater than 400 corrected spots per well at one month
post-vaccination yields a 97% certainty that long-term fol-
low-up responses will be positive. The increases from
baseline interferon gamma Elispot responses against
HER2/neu were also significantly higher in patients that
achieved persistent immunity at long-term follow-up
time points (p < 0.05).
Conclusions
The magnitude of interferon gamma Elispot responses
from peripheral blood mononuclear cells one month after
completion of vaccination correlates best with persistent
immunity at long-term follow-up time points. Pre-existing
levels of immunity also influence the ability of patients to
achieve persistent immunity at long-term follow-up with
therapeutic vaccination. This knowledge may be exploited
to identify the success of targeted cancer vaccines early
and allow the implementation of boosters or the employ-
ment of vaccines against alternate targets.
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